StockData
Disc Medicine, Inc. logo

Disc Medicine, Inc. (IRON) stock

IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$76.57−0.02 (-0.03%)

Close on Nov 17, 2026Market cap $2.94BP/E –Yield –

Disc Medicine ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Disc Medicine's ebitda for the twelve months ending Jun 30, 2026 was -$268.91M. For fiscal 2025 it was -$235.74M. The highest annual figure on record is -$30.90M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$235.74M–
FY2024Dec 31, 2024-$129.56M–
FY2023Dec 31, 2023-$91.03M–
FY2022Dec 31, 2022-$47.39M–
FY2021Dec 31, 2021-$30.90M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$64.99M–
Q1 FY2026Mar 31, 2026-$69.44M–
Q4 FY2025Dec 31, 2025-$66.88M–
Q3 FY2025Sep 30, 2025-$67.61M–
Q2 FY2025Jun 30, 2025-$61.33M–
Q1 FY2025Mar 31, 2025-$39.93M–
Q4 FY2024Dec 31, 2024-$34.54M–
Q3 FY2024Sep 30, 2024-$32.85M–
Q2 FY2024Jun 30, 2024-$30.74M–
Q1 FY2024Mar 31, 2024-$31.44M–
Q4 FY2023Dec 31, 2023-$29.69M–
Q3 FY2023Sep 30, 2023-$18.93M–
Q2 FY2023Jun 30, 2023-$17.30M–
Q1 FY2023Mar 31, 2023-$25.10M–
Q4 FY2022Dec 31, 2022-$15.00M–
Q3 FY2022Sep 30, 2022-$10.46M–
Q2 FY2022Jun 30, 2022-$11.99M–
Q1 FY2022Mar 31, 2022-$9.94M–

More Disc Medicine figures

See a number that looks wrong?